HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))

Subscribe to New Research on 2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine

Also Known As:

d(AT); d(A-T); (d(AT)10)2; (dApT); DTL-DAD; TA(asterisk); d(TpA); dTpdA; deoxyadenylyl-3'.5'-deoxythymidylic acid; deoxyadenylyl-3'5'-deoxythymidylate; Adenosine, thymidylyl-(3'-5')-2'-deoxy-

Networked: 817 relevant articles (49 outcomes, 110 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 2866
  - Dinucleoside Phosphates: 5
    - 2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine: 817

Experts

1.	Mauri, Laura: 12 articles (10/2015 - 12/2010)
2.	Valgimigli, Marco: 11 articles (09/2015 - 12/2011)
3.	Bhatt, Deepak L: 9 articles (08/2015 - 06/2010)
4.	Mehran, Roxana: 8 articles (07/2015 - 10/2011)
5.	Jang, Yangsoo: 8 articles (07/2015 - 01/2012)
6.	Kereiakes, Dean J: 7 articles (10/2015 - 01/2010)
7.	Baber, Usman: 7 articles (09/2015 - 10/2012)
8.	Hong, Myeong-Ki: 7 articles (06/2015 - 06/2012)
9.	Yeh, Robert W: 6 articles (10/2015 - 08/2012)
10.	Kim, Hyo-Soo: 6 articles (09/2015 - 01/2012)

Related Diseases

1.	Hemorrhage 02/01/2013 - "Based on existing observational studies the rates of major and any bleeding associated with TT are clinically important and significantly greater than those reported with DAPT." 02/01/2015 - "Although reduced DAPT durations continue to show promising results in preventing ischemic events while also mitigating bleeding risk, ultimately the consideration of clinical presentation as well as medical and social history is paramount to guiding the optimal duration and cessation of DAPT. " 10/01/2015 - "Due to selective outcome reporting and variable follow-up, other outcomes of interest could not be meta-analyzed; however, evaluation of individual studies demonstrated no significant reduction in thrombotic events with DAPT and a similar or higher risk of bleeding. " 05/01/2015 - "DAPT offered a significant reduction of major bleeding at 1 year for overall studies and for the subset of observational works providing adjusted data (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.39 to 0.68, I2 60% and OR 0.36, 95% CI 0.28 to 0.46) compared to TT. " 02/15/2015 - "Pooling trials of 3-6 months of DAPT against 12 months, we found a significant reduction in the risk of total bleeding (RR 0.61, 95% CI 0.43-0.87). "
2.	Thrombosis (Thrombus) 12/01/2015 - "The administration of long period of DAPT is a strategy to reduce thrombosis events but largely increase the hemorrhagic ones. " 07/01/2015 - "The cause of thrombus formation in this series was delayed healing process, but other possible triggers included restenosis, insufficient DAPT duration, neoatherosclerosis, and vasospasm. " 01/01/2014 - "On the basis of recent clinical studies, a shorter course of DAPT than recommended by the guidelines (at least 12 months in the ACCF/AHA/SCAI guideline and 6-12 months in the European Society of Cardiology guidelines) may be considered, especially with second-generation or newer-generation DESs being associated with a significant reduction in stent thrombosis compared with first-generation DES. " 08/01/2014 - "These results suggest that the incidence of stent thrombosis in DES trials should not be evaluated independently of DAPT use, and the optimal duration of DAPT will likely depend upon stent type (Clinicaltrials.gov number NCT00476957)." 07/15/2014 - "Studies have suggested that early discontinuation of DAPT can result in an increased risk of stent thrombosis. "
3.	Stroke (Strokes) 10/01/2015 - "Early initiation of DAPT proved beneficial in reducing future ischemic events in the FASTER and CHANCE trials; however, these trials did not provide enough evidence to recommend the routine use of DAPT in secondary stroke prevention, and current guidelines recommend against such therapy. " 07/01/2013 - "Patients with TT was associated with significant reduction in ischemic stroke (OR: 0.27; 95%CI: 0.13 - 0.57; P = 0.0006) as compared to DAPT. " 05/01/2013 - "In our study, for all patients, >12-month DAPT in patients who had received DES was not significantly more effective than 12-month DAPT in reducing the rate of death/MI/stroke. " 11/01/2015 - "Nowadays the dual antiplatelet therapy (DAPT) becomes more widely used in patients with ischemic stroke. " 10/01/2015 - "However, the role for DAPT in the setting of ischemic stroke and TIA is less clear. "
4.	Myocardial Infarction 07/21/2015 - "Moderate-quality evidence showed that longer-duration DAPT decreased risk for myocardial infarction (risk ratio [RR], 0.73 [95% CI, 0.58 to 0.92]) and increased mortality (RR, 1.19 [CI, 1.04 to 1.36]). " 05/01/2015 - "Treatment with DAPT is recommended for both ST-elevation myocardial infarction and non-ST-elevation ACS, as well as after PCI with stenting, in American and European clinical guidelines. " 01/01/2015 - "We document dual antiplatelet therapy (DAPT) use from discharge to 4 years after acute myocardial infarction (AMI), and investigate whether prolonged DAPT (beyond 1 year) is related to 5-year mortality. " 01/01/2014 - "To evaluate the clinical utility of individualising dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in an all-comers population, including ST-elevation myocardial infarction (STEMI) patients. " 01/01/2014 - "No significant increase in the composite endpoint of death and nonfatal myocardial infarction was observed with earlier cessation of DAPT in any instance when compared to longer durations of DAPT (RR 0.64 95% CI 0.25-1.63 for 3 versus 12 months, RR 1.09 95% CI 0.84-1.41 for 6 versus 12 months and, RR 0.64 95% CI 0.35-1.16 for 12 versus 24 months). "
5.	Coronary Artery Disease (Coronary Atherosclerosis) 02/15/2013 - "This study was designed to evaluate the association of varying durations of DAPT on clinical outcomes after DES implantation for the treatment of coronary artery disease. " 08/01/2011 - "This was a prospective, randomized, double-blind, parallel design study conducted in DM patients with stable coronary artery disease receiving DAPT. " 12/01/2015 - "Nevertheless, the treatment of stable/unstable coronary artery disease with DES implantation increasing largely, the optimal duration of DAPT is still unclear. " 10/01/2015 - "In patients receiving DAPT for coronary artery disease, p-LCR does not impact platelet reactivity. " 08/01/2015 - "Patients in the >3 DAPT prescribed group were older, had preexisting coronary artery disease (CAD), and prior MI (all P < 0.001). "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	clopidogrel (Plavix)
3.	omega-Chloroacetophenone (Mace)
4.	cilostazol (Pletal)
5.	Amyloid Precursor Protein Secretases (beta-Secretase)
6.	Warfarin (Coumadin)
7.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
8.	rivaroxaban
9.	tyrosine-4-azophenyltrimethylammonium chloride (TAPT)
10.	HMGB1 Protein (HMG1)

Related Therapies and Procedures

1.	Stents
2.	Laser In Situ Keratomileusis (LASIK)
3.	Photorefractive Keratectomy
4.	Gastric Bypass (Roux-en-Y Gastric Bypass)
5.	Drug-Eluting Stents